STOML2 regulates autophagy through the PARL/PINK1 pathway, thereby reducing the chemoresistance of pancreatic cancer. Overexpression of STOML2 as a targeted therapy may help sensitize gemcitabine in the future. Here, PARL is linked to pancreatic neoplasm.